Antithrombotic Therapy After Revascularization in Patients With Peripheral Arterial Disease: What Is Here, What Is Next
| Autor: | Saurabh Joshi, Surya Teja Chaturvedula, Joseph Ingrassia, Mostafa R. Amer |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Arterial disease medicine.medical_treatment Hemorrhage 030204 cardiovascular system & hematology Revascularization Drug Administration Schedule law.invention Peripheral Arterial Disease 03 medical and health sciences Antithrombotic treatment 0302 clinical medicine Fibrinolytic Agents Randomized controlled trial Risk Factors law Internal medicine Antithrombotic medicine Humans In patient 030212 general & internal medicine Blood Coagulation business.industry Anticoagulants General Medicine Peripheral Regimen Treatment Outcome Cardiology Drug Therapy Combination Surgery Cardiology and Cardiovascular Medicine business Vascular Surgical Procedures Platelet Aggregation Inhibitors |
| Zdroj: | Vascular and Endovascular Surgery. 53:325-336 |
| ISSN: | 1938-9116 1538-5744 |
| DOI: | 10.1177/1538574419836316 |
| Popis: | Objective: The optimal antithrombotic regimen in peripheral arterial disease (PAD) is not known, leading to significant variations in antithrombotic treatment protocols in randomized trials and clinical practice. In device trials, antithrombotic regimens in patients receiving peripheral vascular interventions have not been clearly reported on. This review summarizes and discusses the most recent evidence on this topic to provide a potential guide to clinical practice. Methods: A search of the literature was done for publications that reported outcomes of major PAD device trials. Reported outcomes and various antithrombotic regimens were studied. Results: Use of antithrombotic therapy varied significantly between various device trials. Reporting of antithrombotic regimens at the time of follow-up is lacking. Conclusion: Outcome data on optimal antithrombotic regimens are presently lacking largely due to the significant heterogeneity and underreporting of antithrombotic regimens at follow-up among prior clinical trials. Standardization and reporting of precise antithrombotic regimens at various points of follow-up in device trials of patients with PAD should be attempted so as to minimize differences in treatment patterns when evaluating new devices. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|